<DOC>
	<DOCNO>NCT00537576</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability acceptability new formulation Lactobacillus crispatus , strain CTV-05 ( LACTIN-V ) healthy pre-menopausal woman . Osel , Inc. propose new formulation safe well-tolerated healthy pre-menopausal woman .</brief_summary>
	<brief_title>Safety Study Lactobacillus Administered Vaginally Healthy Women</brief_title>
	<detailed_description>The purpose study demonstrate new formulation L. crispatus CTV-05 ( LACTIN-V ) safe well tolerate healthy pre-menopausal woman administer vaginally via pre-filled applicator dose 5.0 x 10^8 , 1.0 x 10^9 2.0 x 10^9 cfu/dose daily 5 consecutive day compare placebo control substance contain maltodextrin preservation matrix . Safety assess : - Incidence severity adverse event assess symptom , physical examination finding , sign irritation involve external genitalia , cervix vagina , include disruption epithelium blood vessel see pelvic examination colposcopy . - Laboratory parameter include urinalysis , complete blood count ( CBC ) differential , chemistry panel assess systemic effect study product . The study also evaluate tolerability acceptability LACTIN-V pre-filled applicator : - The proportion participant discontinue study product use due overt adverse event - The proportion participant adhere complete dose schedule - Self-administered questionnaire focus group discussion acceptability study product</detailed_description>
	<mesh_term>Vaginosis , Bacterial</mesh_term>
	<criteria>Healthy premenopausal woman 18 40 year age date screening . Regular menstrual cycle ( 2135 day ) amenorrheic least 3 month due use long act progestin continuous use oral contraceptive . Subject willing insert prefilled vaginal applicator . Subject willing ask question personal medical health sexual history . Normal Pap smear collect screening visit . Vaginal cervical anatomy opinion Investigator lend easily colposcopy . Capable provide informed consent read English . Previous sexual experience include vaginal intercourse . Previous experience gynecological examination . Currently mutually monogamous sexual relationship sexually active . Agree sexually abstinent 72 hour prior Visit 1 ( enrollment ) Visit 3 ( Day 14 ) . Agree abstain use intravaginal product ( i.e. , contraceptive cream , gel , foam , sponge , lubricant , douche , etc . ) throughout trial period , time screen Day 35 . Agree use tampon throughout trial period , time screen Day 35 . Agree use adequate method birth control duration study avoid pregnancy . Acceptable method include history tubal ligation , male partner vasectomy , steroidal contraceptive ( oral , patch , injectable implantable ) , IUD ( Paragard Mirena ) , use condoms abstinence . Urogenital infection screen within 21 day prior screen . This include urinary tract infection , bacterial vaginosis , Trichomonas vaginalis , Neisseria gonorrhoeae , Chlamydia trachomatis , Treponema pallidum Herpes simplex . Subjects may rescreened least 21 day respective antibiotic antifungal therapy complete . History recurrent genital herpes . Diagnosis N. gonorrhoeae , C. trachomatis , T. pallidum T. vaginalis two occasion six month prior screen . Pregnancy within 2 month last pregnancy ( subject urine pregnancy test prior enrollment ) . Lactation . Antibiotic antifungal therapy within 30 day enrollment visit ( vaginal systemic ) . Investigational drug use within 30 day 10 halflives drug , whichever longer , enrollment visit . Planned investigational drug participate study . Menopause . IUD insertion removal within last 3 month . Pelvic surgery within last 3 month . Cervical cryotherapy cervical laser within last 3 month . Use NuvaRingÂ® within 3 day screen visit course study . New longacting treatment ( e.g . depot formulation include medroxyprogesterone acetate ( DMPA ) form hormonal birth control ) . Subjects may enrol stable ( &gt; 3months ) exist therapy determine Principal Investigator . Diabetes significant disease acute illness Investigator 's assessment could complicate evaluation . Known HIV infection positive HIV test screening . Immunosuppressive drug within 60 day . Previous participation L. crispatus CTV05 clinical study . Colposcopic finding enrollment visit involve significant deep disruption epithelium . Abnormal result pap smear screen visit . Known allergy component LACTINV , significant drug allergy latex ( condom ) . Unavailable followup visit . Known drug alcohol abuse . At enrollment , social medical condition ( e.g. , neurological , gastrointestinal , renal , hepatic , cardiovascular , pulmonary , metabolic , endocrine , hematological , genitourinary major disorder ) , psychiatric illness ( e.g. , depression , schizophrenia ) , opinion Investigator , would preclude provision inform consent , make participation study unsafe , complicate interpretation study outcome data , otherwise interfere achieve study objective .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>June 2008</verification_date>
</DOC>